42 / 154
S12
A B S T R A C T S
population based analysis showed that for limited stage
small cell lung cancer selected elderly patients could tolerate
chemoradiotherapy and this confers a survival benefit over
chemotherapy alone. Extensive stage SCLC is managed only
by palliative chemotherapy or best supportive care in non-fit
older individuals.
Disclosure of interest:
None declared
S34
UPDATES IN GERIATRICS
Stefania Maggi
CNR, Medicine, Aging Branch, Padua, Italy
This presentation will focus on the description of global
trends in population ageing, considering that the twenty-first
century will witness even more rapid ageing than did the
century just past. The shift in age structure associated with
population aging has a profound impact on a broad range of
economic, political and social conditions (World Population
Ageing 1950–2050. Population Division, DESA, United Nations).
As more people live longer, retirement, pensions and other
social benefits tend to extend over longer periods of time.
This makes necessary for social security systems to change in
order to remain effective. Increasing longevity can also result
in rising medical costs and increasing demands for health
services, since older people are typically more vulnerable to
chronic diseases. The demographic causes of aging of the
population, in terms of fertility rates and mortality rates, are
generally predictable. A variety of population projections are
available, prepared by UN, EU and National Statistic Institutes.
What is less predictable is the interaction of these forces with
social context, health status, economic changes, cultural
influences and hence international migrations. Martin et al,
considering data from the NHANES and the NHIS, conclude
that health and disability of elderly improved during the last
two decades of 20th century. At the same time, population
aged 40–64 years has not shown a consistent improvement
and there is some evidence of increase in disability in this age
group (Martin LG, Schoeni RF, Andreski PM, 2010), therefore
suggesting a potential worsening of the health status in the
future cohort of older individuals.
Disclosure of interest:
None declared
S35
Michele Maio
The speaker abstract has not been received at the time of
publication.
S36
FOLLICULAR NHL IN THE ELDERLY: ROLE OF GERIATRIC
ASSESSMENT AND THERAPY
Marco Ladetto
The speaker abstract has not been received at the time of
publication.
S37
Christophe Massard
DITEP, Villejuif, France
The speaker abstract has not been received at the time of
publication.
Disclosure of interest:
Participation to advisory boards,
speaker, or investigator for: Amgen, Astellas, Astra Zeneca,
Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer,
Roche, Sanofi, Orion
S38
Christophe Massard
DITEP, Villejuif, France
The speaker abstract has not been received at the time of
publication.
Disclosure of interest:
Participation to advisory boards,
speaker, or investigator for: Amgen, Astellas, Astra Zeneca,
Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer,
Roche, Sanofi, Orion
S39
COMPREHENSIVE GERIATRIC ASSESSMENT AS
STRATIFICATION TOOL IN ELDERLY PATIENTS WITH
HAEMATOLOGICAL MALIGNANCIES
Francesco Merli
Hematology Unit, Oncology and Advanced Technologies, Denmark
Hematological malignancies (HM) are a heterogeneous
group of diseases of different incidence, prognosis and
etiology.
Among them, chronic lymphocytic leukemia (CLL) and
diffuse large B cell lymphoma (DLBCL) are the most frequent
HM observed in elderly patients. For both CLL and DLBCL,
standard therapies are available and are usually proposed to
FIT patients to achieve the best quality of response, the longest
Progression Free Survival in CLL and the higher cure rates in
DLBCL. Standard therapies however are also associated to
adverse events that are manageable in young FIT patients,